반응식
[CH:1]1([CH2:4][O:5][C:6]2[N:11]=[C:10]([C:12](O)=[O:13])[CH:9]=[CH:8][C:7]=2[N:15]2[C:18]3([CH2:21][O:20][CH2:19]3)[CH2:17][CH2:16]2)[CH2:3][CH2:2]1.[CH3:22][C:23]([CH3:31])([C:25]1[N:29]=[C:28]([CH3:30])[O:27][N:26]=1)[NH2:24]>>[CH3:22][C:23]([NH:24][C:12]([C:10]1[CH:9]=[CH:8][C:7]([N:15]2[C:18]3([CH2:19][O:20][CH2:21]3)[CH2:17][CH2:16]2)=[C:6]([O:5][CH2:4][CH:1]2[CH2:3][CH2:2]2)[N:11]=1)=[O:13])([C:25]1[N:29]=[C:28]([CH3:30])[O:27][N:26]=1)[CH3:31]참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was synthesized in analogy to Example 1, using 6-(cyclopropylmethoxy)-5-(6-oxa-1-azaspiro[3.3]heptan-1-yl)picolinic acid (Example 234 b) and α,α,5-trimethyl-1,2,4-oxadiazole-3-methanamine (CAN 1153831-97-0) as starting materials. MS (EI): m/e=414.1 [M+H]+.
출처 및 근거
- ORD 기록
- ord-132d2c4b614d40afb625000e0850fb5b
- 출처 데이터셋
- uspto-grants-2016_04
- 특허 번호
- US09321727B2
연결된 노트
불러오는 중…